Q1 2025 Earnings Forecast for FibroGen, Inc. Issued By William Blair (NASDAQ:FGEN)

FibroGen, Inc. (NASDAQ:FGEN) – Research analysts at William Blair cut their Q1 2025 earnings estimates for shares of FibroGen in a note issued to investors on Tuesday, May 7th. William Blair analyst A. Hsieh now anticipates that the biopharmaceutical company will earn $0.00 per share for the quarter, down from their prior estimate of $0.04. William Blair currently has a “Market Perform” rating on the stock. The consensus estimate for FibroGen’s current full-year earnings is ($1.09) per share.

FibroGen (NASDAQ:FGEN) last announced its quarterly earnings data on Monday, February 26th. The biopharmaceutical company reported ($0.57) earnings per share for the quarter, missing the consensus estimate of ($0.42) by ($0.15). The firm had revenue of $27.14 million during the quarter, compared to analyst estimates of $40.00 million.

FibroGen Price Performance

Shares of FGEN opened at $1.22 on Thursday. The firm’s 50 day moving average is $1.67 and its 200-day moving average is $1.24. FibroGen has a 12-month low of $0.33 and a 12-month high of $19.47. The stock has a market capitalization of $121.36 million, a P/E ratio of -0.50 and a beta of 0.88.

Insider Buying and Selling

In related news, CEO Thane Wettig purchased 50,000 shares of the company’s stock in a transaction on Thursday, March 7th. The shares were bought at an average price of $1.91 per share, with a total value of $95,500.00. Following the completion of the acquisition, the chief executive officer now owns 470,178 shares of the company’s stock, valued at $898,039.98. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 1.98% of the stock is currently owned by insiders.

Institutional Investors Weigh In On FibroGen

A number of institutional investors and hedge funds have recently modified their holdings of FGEN. Assenagon Asset Management S.A. raised its holdings in FibroGen by 49.7% during the 3rd quarter. Assenagon Asset Management S.A. now owns 2,226,857 shares of the biopharmaceutical company’s stock worth $1,922,000 after buying an additional 739,166 shares during the period. Public Employees Retirement System of Ohio increased its position in shares of FibroGen by 1,472.7% in the third quarter. Public Employees Retirement System of Ohio now owns 176,593 shares of the biopharmaceutical company’s stock worth $152,000 after acquiring an additional 165,364 shares in the last quarter. Primecap Management Co. CA raised its holdings in shares of FibroGen by 7.7% during the third quarter. Primecap Management Co. CA now owns 14,724,968 shares of the biopharmaceutical company’s stock valued at $12,706,000 after acquiring an additional 1,047,380 shares during the period. Armistice Capital LLC lifted its position in shares of FibroGen by 81.2% in the 3rd quarter. Armistice Capital LLC now owns 7,892,000 shares of the biopharmaceutical company’s stock valued at $6,810,000 after acquiring an additional 3,536,000 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. acquired a new position in FibroGen in the 3rd quarter worth approximately $94,000. 72.71% of the stock is owned by institutional investors and hedge funds.

FibroGen Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.